<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04743076</url>
  </required_header>
  <id_info>
    <org_study_id>BASILAR-2</org_study_id>
    <nct_id>NCT04743076</nct_id>
  </id_info>
  <brief_title>A Randomized Trial Of Endovascular Treatment For Acute Posterior Large Vessel Occlusion</brief_title>
  <acronym>BASILAR-2</acronym>
  <official_title>Standard Medical Treatment Plus Endovascular Treatment Versus Standard Medical Treatment Alone for Stroke Patient With Large Vessel Occlusion In The Posterior Circulation: A Multicenter, Randomized, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinqiao Hospital of Chongqing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to investigate whether endovascular treatment can improve the 90-day&#xD;
      functional outcome of acute large vessel occlusion in the posterior circulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At least seven randomized controlled trials have consistently shown that endovascular&#xD;
      treatment can improve the functional outcome of stroke patients with acute anterior large&#xD;
      vessel occlusion. However, these trials did not include patients with large vessel occlusion&#xD;
      in the posterior circulation.&#xD;
&#xD;
      The hypothesis of this trial: Compared with standard medical treatment alone, standard&#xD;
      medical treatment combined with endovascular treatment can significantly improve the 90-day&#xD;
      functional outcome of acute large vessel occlusion in the posterior circulation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Withdrawal of funding&#xD;
  </why_stopped>
  <start_date type="Actual">March 16, 2021</start_date>
  <completion_date type="Anticipated">May 16, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 16, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin scale score</measure>
    <time_frame>90 days</time_frame>
    <description>disability level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of a score of 0~2 on modified Rankin scale</measure>
    <time_frame>90 days</time_frame>
    <description>Functional independence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in NIHSS between baseline and 24 hours</measure>
    <time_frame>at 24 hours from randomization</time_frame>
    <description>neurological changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in NIHSS between baseline and 5~7d</measure>
    <time_frame>at 5~7 days from randomization</time_frame>
    <description>neurological changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in GCS between baseline and 24 hours</measure>
    <time_frame>at 24 hours from randomization</time_frame>
    <description>neurological changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in GCS between baseline and 24 hours</measure>
    <time_frame>at 5~7 days from randomization</time_frame>
    <description>neurological changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asymptomatic intracranial hemorrhage within 48 hours</measure>
    <time_frame>within 48 hours after endovascular treatment</time_frame>
    <description>evaluate intracranial hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural-related complications and severe adverse events</measure>
    <time_frame>within 90 days</time_frame>
    <description>evaluate complications and any adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious non-hemorrhagic adverse events</measure>
    <time_frame>within 90 days</time_frame>
    <description>evaluate complications and any adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of 90-day EQ-5D scale</measure>
    <time_frame>90 days</time_frame>
    <description>Functional independence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality within 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>evaluate death rate of the two treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracranial hemorrhage within 48 hours</measure>
    <time_frame>within 48 hours after endovascular treatment</time_frame>
    <description>evaluate intracranial hemorrhage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">386</enrollment>
  <condition>Vertebrobasilar Stroke</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard medical treatment plus endovascular treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard medical treatment alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endovascular treatment</intervention_name>
    <description>Endovascular treatment</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard medical treatment</intervention_name>
    <description>Standard medical treatment</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: i. 18 ~ 80 years old, pc-ASPECTS score ≥ 6; ii. &gt; 80 years old, pc-ASPECTS score&#xD;
             ≥ 8 and mRS = 0 before the onset&#xD;
&#xD;
          2. NIHSS score ≥ 10 before randomization;&#xD;
&#xD;
          3. VA-V4 or basilar artery occlusion proved by CTA/MRA/DSA;&#xD;
&#xD;
          4. Time from stroke onset to randomization within 23.5 hours;&#xD;
&#xD;
          5. Written informed consent is obtained from patients and/or their legal representatives.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. CT or MR evidence of intracranial hemorrhage;&#xD;
&#xD;
          2. Pre-morbidity with a modified Rankin scale score ≥ 3;&#xD;
&#xD;
          3. The patient is in deep coma;&#xD;
&#xD;
          4. Currently in pregnant or lactating or serum beta HCG test is positive on admission;&#xD;
&#xD;
          5. Arterial tortuosity and/or other arterial disease that would prevent the device from&#xD;
             reaching the target vessel;&#xD;
&#xD;
          6. Contraindication to radiographic contrast agents, nickel, titanium metals or their&#xD;
             alloys;&#xD;
&#xD;
          7. Significant mass effect in the cerebellar hemisphere or hydrocephalus on imaging;&#xD;
&#xD;
          8. Imaging manifestations of diffuse bilateral brainstem ischemia;&#xD;
&#xD;
          9. Multivessel occlusive disease (combined with anterior and posterior circulation&#xD;
             occlusion or subtotal occlusion);&#xD;
&#xD;
         10. Cerebral vasculitis, intracranial arteriovenous malformation, aneurysm, or brain tumor&#xD;
             with mass effect;&#xD;
&#xD;
         11. Participating in other clinical trials;&#xD;
&#xD;
         12. Any terminal illness with life expectancy less than 6 months;&#xD;
&#xD;
         13. Patients with a preexisting neurological or psychiatric disease that would confound&#xD;
             the neurological functional evaluations;&#xD;
&#xD;
         14. Past neurological or psychiatric diseases that hinder the assessment of neurological&#xD;
             function;&#xD;
&#xD;
         15. Unlikely to be available for 90-day follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qingwu Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology, Xinqiao Hospital of the Army Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wenjie Zi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology, Xinqiao Hospital of the Army Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raul G Nogueira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marcus Stroke &amp; Neuroscience Center, Grady Memorial Hospital, Emory University, Atlanta, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey L Saver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology, University of California, Los Angeles, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yijishan Hospital of Wannan Medical College</name>
      <address>
        <city>Wuhu</city>
        <state>Anhui</state>
        <zip>241000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banan District People's Hospital</name>
      <address>
        <city>Banan</city>
        <state>Chongqing</state>
        <zip>400040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xinqiao Hospital of Army Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuyi Traditional Chinese Medicine Hospital</name>
      <address>
        <city>Jiangmen</city>
        <state>Guangdong</state>
        <zip>529000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangmen Central Hospital</name>
      <address>
        <city>Jiangmen</city>
        <state>Guangdong</state>
        <zip>529030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maoming Traditional Chinese Medicine Hospital</name>
      <address>
        <city>Maoming</city>
        <state>Guangdong</state>
        <zip>525000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese Medical Hospital of Zhongshan</name>
      <address>
        <city>Zhongshan</city>
        <state>Guangdong</state>
        <zip>528400</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 924th Hospital of CPLA</name>
      <address>
        <city>Guilin</city>
        <state>Guangxi</state>
        <zip>541000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danzhai People's Hospital</name>
      <address>
        <city>Danzhai</city>
        <state>Guizhou</state>
        <zip>557500</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanyang Central Hospital</name>
      <address>
        <city>Nanyang</city>
        <state>Henan</state>
        <zip>473000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan No. 1 Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 904th Hospital of CPLA</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xuzhou Central Hospital</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Southwest Medical University</name>
      <address>
        <city>Luzhou</city>
        <state>Sichuan</state>
        <zip>646000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Writing Group for the BASILAR Group, Zi W, Qiu Z, Wu D, Li F, Liu H, Liu W, Huang W, Shi Z, Bai Y, Liu Z, Wang L, Yang S, Pu J, Wen C, Wang S, Zhu Q, Chen W, Yin C, Lin M, Qi L, Zhong Y, Wang Z, Wu W, Chen H, Yao X, Xiong F, Zeng G, Zhou Z, Wu Z, Wan Y, Peng H, Li B, Hu X, Wen H, Zhong W, Wang L, Jin P, Guo F, Han J, Fu X, Ai Z, Tian X, Feng X, Sun B, Huang Z, Li W, Zhou P, Tu M, Sun X, Li H, He W, Qiu T, Yuan Z, Yue C, Yang J, Luo W, Gong Z, Shuai J, Nogueira RG, Yang Q. Assessment of Endovascular Treatment for Acute Basilar Artery Occlusion via a Nationwide Prospective Registry. JAMA Neurol. 2020 May 1;77(5):561-573. doi: 10.1001/jamaneurol.2020.0156.</citation>
    <PMID>32080711</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinqiao Hospital of Chongqing</investigator_affiliation>
    <investigator_full_name>Zhongming Qiu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>endovascular treatment</keyword>
  <keyword>thrombolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>study data without patient information</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Related papers published 3 months later, the IPD will be shared</ipd_time_frame>
    <ipd_access_criteria>yangqwmlys@163.com ziwenjie1981@163.com</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

